QIAGEN Introduces Novel Modular Processing Platform
Jan 28 2008

QIAGEN Introduces Novel Modular Processing Platform

QIAsymphony® SP offers highest flexibility, convenience and safety for a broad range of sample and assay applications

Venlo, The Netherlands, January 28, 2008 --- QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the launch of QIAsymphony® SP, the first system of a novel modular platform which offers laboratories a new level of flexibility, convenience and safety in automated processing of a broad range of molecular sample and assay applications. With QIAsymphony SP, QIAGEN is launching the first module in its new series of modular instruments which can be integrated to automate entire workflows - from sample to result. The QIAsymphony is the result of the largest development program ever undertaken at QIAGEN. The system is currently designed to meet users' needs in the areas of applied testing, pharmaceutical and life science research. Following the validations and filings required in the respective countries, QIAGEN will further expand the use of the platform into the molecular diagnostics market.

QIAsymphony SP allows users to load samples in many formats and of many types and to isolate, purify and prepare target analytes for further analysis. This step is considered by far the most challenging in any molecular analysis. QIAsymphony SP is designed to meet labs' increasing flexibility and workflow needs. The system enables the handling of an extensive variety of starting materials and a wide range of input volumes. Over 40 protocols to process DNA, RNA and proteins have been optimized for use on the QIAsymphony. The system has incorporated many first-of-their-kind features in molecular processing including the essential features of continuous loading of sample racks, reagents and consumables, and the ability to perform several purification procedures on one batch of samples without reloading reagents (random access). The system is designed to provide value in a wide bandwidth of throughput settings, from a few samples a day up to a few hundred.

QIAsymphony SP is a system that performs the most advanced processes but at the same time can be operated by a novice without the need for costly retraining of laboratory staff. Touch screen operations provide highest convenience and bar codes allow easy tracking of samples and reagents, guaranteeing maximum safety and reproducible results.

"We are very excited to unveil our QIAsymphony platform and with it the first module: QIAsymphony SP. Standardization and process safety are key for today's labs", says Peer Schatz, CEO of QIAGEN. "Cutting-edge technologies, innovative functions and proven QIAGEN chemistries make the QIAsymphony a truly unique solution and create a strong basis for further expansion of our already broad and leading offering of automated sample & assay technologies."

QIAsymphony was launched together with two other QIAGEN automation platforms: QIAxcel and EZ1 Advanced at LabAutomation 2008, the world's largest conference for laboratory automation held in Palm Springs January 27-30. The Company's platform portfolio also includes the QIAcube, a versatile and compact system which was launched in 2007 for the low- to medium-throughput range as well as the QIAGEN BioRobot series (BioRobot Universal System and BioRobot MDx) for high throughput requirements.

About QIAsymphony

  • Cutting-edge technology, innovative functions and proven and leading QIAGEN chemistries for highest-performance results
  • QIAsymphony SP is the first element launched of a modular system designed to automate whole workflows from sample to result
  • New level of flexibility in sample processing and applications
  • Features touch screen operations, bar-coding of samples and reagents
  • Process allows continuous loading of 1 to 96 samples per run
  • Random access processing of multiple protocols without reloading reagents
  • Pictures are available at http://www.qiagen.com/goto/qiasymphonyimages/

QIAsymphony SP is intended to be used only in combination with QIAsymphony SP Kits for applications described in the respective QIAsymphony SP Kit handbook. QIAsymphony SP Kits are intended for laboratory use. No claim or representation is intended for its use to provide information for the diagnosis, prevention, or treatment of a disease.


QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products. The products are considered standards in areas such as pre-analytical sample preparation and molecular diagnostics solutions. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Dr. Solveigh Mähler Albert F. Fleury Dr. Thomas Theuringer  
Director Investor Relations Investor Relations North America Associate Director Public Relations  
+49 2103 29 11710 +1 301 944 7028 +49 2103 29 11826  
e-mail: solveigh.maehler@qiagen.com e-mail: albert.fleury@qiagen.com e-mail: thomas.theuringer@qiagen.com  

Share this page